UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study

Table 1 Clinical background: UGT1A1 genotype and clinical characteristics

UGT1A1		Total	UGT1A1 wild-type	UGT1A1 polymorphism (hetero/homo type)	P-value
Number (%)		51	24 (47.0%)	23/4 (45.1%/7.8%)
Age, years	Average (min-max)	52.2	52.3 (36–64)	52.1 (29–78)	0.96
FIGO stage	IB1–2	24 (47.1%)	11	13	0.56
	IIA	2 (3.9%)	0	2
	IIB	25 (49.0%)	13	12
Lymph node metastasis	None	38 (74.5%)	17	21	0.44
	Pelvic nodes	11 (21.5%)	5	6
	Para-aortic nodes	2 (3.9%)	2	0

FIGO Federation of Gynecology and Obstetrics, UGT1A1 Uridine diphosphate glucuronosyltransferase 1 family polypeptide A1

ISSN: 1471-2407